Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Puvatherapy vs placebo or no treatment

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 22 participants
Very low

Puvatherapy vs placebo or no treatment

Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wax therapy vs foot soaks

Ulcer healing · skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wax therapy vs foot soaks

Tertiary outcome: prevention and treatment of other skin changes (number of feet being fissure‐ and callous‐free at 6 weeks) · skin changes caused by nerve damage in leprosy

It is very uncertain whether wax therapy changes tertiary outcome: prevention and treatment of other skin changes… compared with foot soaks (very low certainty).

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
RR 2.22 [1.07, 4.6]
1 study · 44 participants
Very low

Wax therapy vs foot soaks

Primary outcome: prevention of ulcer · skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wax therapy vs foot soaks

Adverse events associated with treatment · skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wax therapy vs foot soaks

Secondary outcome: quality of life · skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Wax therapy vs foot soaks

Secondary outcome: acceptability of treatment · skin changes caused by nerve damage in leprosy

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Very low

Wax therapy vs foot soaks

Cost of the intervention · skin changes caused by nerve damage in leprosy

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for ulceration and other skin changes caused by nerve damage in leprosy 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.82 [0.52, 1.27]
7 studies · 859 participants
Moderate

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Pain ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 480 participants
Moderate

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Recurrence · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Time to resolution · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Quality of life · people with telangiectasias and reticular veins

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 852 participants
Moderate

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.94 [0.62, 1.43]
6 studies · 819 participants
Moderate

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
RR 0.03 [0, 0.42]
1 study · 35 participants
Low

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…

1 finding from 1 review

Interventions for morphea 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low